Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Intra-Cellular Therapies

    • Most Recent Events

    • 06 Mar 2023 Results of pooled analysis from NCT01499563, NCT02282761, NCT02469155 published in the Journal of Clinical Psychiatry
    • 07 Jun 2021 Pooled analysis (study 005 [NCT01499563], study 301 [NCT02282761] and study 302 [NCT02469155]) published in the Intra-Cellular Therapies Media Release.
    • 07 Jun 2021 According to an Intra-Cellular Therapies media release, a pooled analysis of 3 randomized, double-blind, placebo-controlled trials (study 005 [NCT01499563], study 301 [NCT02282761] and study 302 [NCT02469155]) was recently published online in International Clinical Psychopharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top